Study Information

How Long is the Study?

Double-Blind Period

26 weeks
  • The total study duration is up to 26 weeks or approximately 6 months including screening, baseline, treatment, and follow-up
    • Up to 4 weeks of screening
    • 8 weeks of baseline assessment
  • You will receive a total of 8 weeks of daily treatment (XEN1101 or placebo) during the double-blind period of the study
  • There will be a 6 week follow-up period after treatment is completed
  • You will need to attend 8-10 clinic visits

Open-Label Extension Period

52 weeks
  • If you are eligible to continue into the open-label extension period of the study, you could receive up to 52 weeks or approximately 1 year of daily treatment
  • Everyone will receive active study drug (XEN1101) during the open-label the extension period of the study
  • There will be a 6 week follow-up period after treatment is completed
  • You will need to attend 7 clinic visits